This article is more than 5 years old. Information may no longer be current.
Neoadjuvant intra-arterial cytoreductive chemotherapy may improve survival in patients with lacrimal gland adenoid cystic carcinoma
Click Here to Manage Email Alerts
Patients with lacrimal gland adenoid cystic carcinoma may be treated with neoadjuvant intra-arterial cytoreductive chemotherapy instead of conventional treatment for improved survival, according to a study.
The retrospective case series included 19 consecutive patients treated with intra-arterial cytoreductive chemotherapy. Disease relapse, disease-free survival and chemotherapeutic complications were all measured.
Eight patients with an intact lacrimal artery had better survival outcomes and recurrences (100% vs. 28.6% at 10 years) than patients treated conventionally. The 11 patients who had an absence of the lacrimal artery had a 50% disease-free survival rate at 10 years.
Intra-arterial cytoreductive chemotherapy reduced tumor size and decreased the tumor burden, according to the study authors.
Disclosure: The study authors report no relevant financial disclosures.
Click Here to Manage Email Alerts